New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues. Fabrizio, S.; Flavia, N.; Stefania, C.; Laura, O.; Amira, G.; Martin, C., J.; Stefania, B.; Angelo, R.; Norbert, S.; and Alessandro, V. Current Addiction Reports, Springer International Publishing, 4, 2019.
New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues [link]Website  abstract   bibtex   
Purpose of the Review A significant increase in the number, type and availability of new psychoactive substances (NPS) with dissociative and psychedelic potential has occurred worldwide over the last few decades. Psychedelic substances have historically been used in order to achieve altered states of consciousness such as dissociative states. We aimed here at describing both a large number of novel ketamine-like dissociatives and tryptamine/lysergamide/phenethylamine psychedelics available, whilst describing the acute/long-term clinical scenarios most commonly associated with their intake. Recent Findings An updated overview of the clinical and clinical pharmacological issues related to some of the most popular NPS categories has been provided, describing both psychosis and remaining psychopathological issues related to them. Conclusions Although the complex link between NPS and psychiatric illnesses is yet to be fully understood, NPS misuse is now a significant clinical issue and an increasing challenge for clinicians working in both mental health and emergency departments.
@article{
 title = {New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues},
 type = {article},
 year = {2019},
 identifiers = {[object Object]},
 pages = {1-13},
 websites = {http://link.springer.com/10.1007/s40429-019-00249-z},
 month = {4},
 publisher = {Springer International Publishing},
 day = {23},
 id = {7b6ca076-e672-3d32-8c87-ecb7aa4d62a2},
 created = {2019-05-05T13:00:45.271Z},
 accessed = {2019-05-05},
 file_attached = {false},
 profile_id = {48f1fda5-0084-39cd-8cc7-68fcbd29ae85},
 group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},
 last_modified = {2019-10-26T10:58:17.344Z},
 tags = {CA,Disc:Psychopharmacology},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {true},
 hidden = {false},
 citation_key = {Fabrizio2019},
 notes = {FL},
 private_publication = {false},
 abstract = {Purpose of the Review A significant increase in the number, type and availability of new psychoactive substances (NPS) with dissociative and psychedelic potential has occurred worldwide over the last few decades. Psychedelic substances have historically been used in order to achieve altered states of consciousness such as dissociative states. We aimed here at describing both a large number of novel ketamine-like dissociatives and tryptamine/lysergamide/phenethylamine psychedelics available, whilst describing the acute/long-term clinical scenarios most commonly associated with their intake. Recent Findings An updated overview of the clinical and clinical pharmacological issues related to some of the most popular NPS categories has been provided, describing both psychosis and remaining psychopathological issues related to them. Conclusions Although the complex link between NPS and psychiatric illnesses is yet to be fully understood, NPS misuse is now a significant clinical issue and an increasing challenge for clinicians working in both mental health and emergency departments.},
 bibtype = {article},
 author = {Fabrizio, Schifano and Flavia, Napoletano and Stefania, Chiappini and Laura, Orsolini and Amira, Guirguis and Martin, Corkery John and Stefania, Bonaccorso and Angelo, Ricciardi and Norbert, Scherbaum and Alessandro, Vento},
 journal = {Current Addiction Reports}
}
Downloads: 0